Article

Addition Technology adds acquired products to Intacs line

Addition Technology Inc. has acquired CooperVision Surgical’s AlphaCor and AlphaSphere and plans to add these products to the Intacs line of corneal implants.

Addition Technology Inc. has acquired CooperVision Surgical’s AlphaCor and AlphaSphere and plans to add these products to the Intacs line of corneal implants.

AlphaCor is a flexible, biointegratable, one-piece artificial cornea designed to replace scarred or diseased native cornea. The product is for patients who have had not responded favorably to multiple corneal transplants and for those patients for whom a donor graft is likely to fail.

AlphaSphere is a soft-biocompatible orbital implant that the company plans to launch later this year. The product is FDA approved for treatment of patients who have lost an eye due to disease or trauma.

Intacs is the only additive corneal implant approved by the FDA for both keratoconus and myopia.

In other news, Addition Technology announced a 55% increase in second quarter 2006 sales of its corneal implants compared with the same quarter the previous year and a 20% increase over the first quarter 2006.

The company has had 13 consecutive quarters of double-digit growth in the United States and international markets.

“With any new technology, the adoption rate builds based upon successful patient outcomes experienced by surgeons,” said William M. Flynn, president and CEO of Addition Technology. “Internationally, we have a strong, technically-oriented distributor network that continues to aggressively train and assist a broad group of corneal surgeons.”

Related Videos
(Image credit: Ophthalmology Times) Neda Shamie_Controversies in Modern Eye Care 2025
(Image credit: Ophthalmology Times) The synergy of cornea, cataract, and refractive surgery through the decades: insights from George O. Waring IV, MD
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
(Image credit: Ophthalmology Times) AGS 2025: Two-year data of bio-interventional cyclodialysis with scleral allograft with Leon W. Herndon Jr, MD
(Image credit: Ophthalmology Times) AGS 2025: Aqueous humor outflow improvement after excimer laser trabeculostomy with Clemens Strohmaier, PhD
(Image credit: Ophthalmology Times) Thomas W. Samuelson, MD, shares clinical perspectives on DSLT, SLT, and glaucoma management
© 2025 MJH Life Sciences

All rights reserved.